Literature DB >> 34567943

Chemoradiotherapy for fistula-related perianal squamous cell carcinoma with Crohn's disease.

Katsuyuki Sakanaka1, Kota Fujii1, Hideaki Hirashima1, Nobutaka Mukumoto1, Hiroyuki Inoo1, Ryo Narukami1, Yoshiharu Sakai2, Takashi Mizowaki1.   

Abstract

The reports of chemoradiotherapy for anal squamous cell carcinoma with Crohn's disease are few. Severe toxicity related to radiotherapy is concerned in patients with inflammatory bowel disease. We report a case of chemoradiotherapy for locally advanced fistula-related perianal squamous cell carcinoma in a patient with long-standing Crohn's disease which was controlled by a maintenance therapy. The patient completed standard chemoradiotherapy using intensity-modulated radiotherapy without severe toxicity, and achieved complete remission. Standard chemoradiotherapy using intensity-modulated radiotherapy may be feasible and effective treatment for this population when Crohn's disease is controlled. © The Japan Society of Clinical Oncology 2021.

Entities:  

Keywords:  Chemoradiotherapy; Crohn’s disease; Fistula-unrelated perianal squamous cell carcinoma

Year:  2021        PMID: 34567943      PMCID: PMC8421484          DOI: 10.1007/s13691-021-00497-9

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  10 in total

1.  Neoplasms of anal canal and perianal skin.

Authors:  Daniel Leonard; David Beddy; Eric J Dozois
Journal:  Clin Colon Rectal Surg       Date:  2011-03

Review 2.  Cancers complicating inflammatory bowel disease.

Authors:  Laurent Beaugerie; Steven H Itzkowitz
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

3.  Abdominal wall recurrence after colorectal resection for cancer.

Authors:  J B Koea; N Lanouette; P B Paty; J G Guillem; A M Cohen
Journal:  Dis Colon Rectum       Date:  2000-05       Impact factor: 4.585

4.  Radiation therapy in patients with inflammatory bowel disease and colorectal cancer: risks and benefits.

Authors:  Bianca W Chang; Aryavarta M S Kumar; Shlomo A Koyfman; Matthew Kalady; Ian Lavery; May Abdel-Wahab
Journal:  Int J Colorectal Dis       Date:  2015-01-08       Impact factor: 2.571

5.  Long-standing Crohn's disease and its implication on anal squamous cell cancer management.

Authors:  Amy L Lightner; Sara B Moncrief; Thomas C Smyrk; John H Pemberton; Michael G Haddock; David W Larson; Eric J Dozois; Kellie L Mathis
Journal:  Int J Colorectal Dis       Date:  2017-03-14       Impact factor: 2.571

6.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

7.  RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.

Authors:  Lisa A Kachnic; Kathryn Winter; Robert J Myerson; Michael D Goodyear; John Willins; Jacqueline Esthappan; Michael G Haddock; Marvin Rotman; Parag J Parikh; Howard Safran; Christopher G Willett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-12       Impact factor: 7.038

Review 8.  Malignant transformation in perianal fistulas of Crohn's disease: a systematic review of literature.

Authors:  Mathew Thomas; Robert Bienkowski; Thomas J Vandermeer; Douglas Trostle; Burt Cagir
Journal:  J Gastrointest Surg       Date:  2009-10-14       Impact factor: 3.452

9.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

10.  Reasons for delays in diagnosis of anal cancer and the effect on patient satisfaction.

Authors:  Sharon Chiu; Kurian Joseph; Sunita Ghosh; Rose-Marie Cornand; Dan Schiller
Journal:  Can Fam Physician       Date:  2015-11       Impact factor: 3.275

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.